Updated: 07 Jan 2001
The Lysosomal Acid Lipase (LAL) Deficiency Knowledge Centre contains a range of accurate, informative clinical content for healthcare professionals. The disease awareness section presents epidemiology, pathophysiology and diagnosis information, among others. The treatment section details the drug characteristics, safety and efficacy of sebelipase alfa – the first and only licenced treatment for LAL deficiency. The resources section contains further clinical content including a video channel presenting expert opinions on diagnostic approach and current prognosis.
Developed by EPG Health Media (Europe) Ltd for epgonline.org, in collaboration and with content provided by Alexion Pharma GmbH
Focusing on the lack of symptomatic control in patients with asthma, the new Symptomatic Asthma Learning Zone, consisting of a Disease Awareness section and an RCGP-accredited CME, is free to access for all epgonline.org members, and has been designed to provide them with the information they need to effectively manage the symptoms of their patients with asthma.
See disease awareness facts and stats, information on sebelipase alfa (the first and only licensed treatment for LAL-D) and resources section, including expert video channel…